1044-90-2 Usage
Description
(3beta,5beta,16alpha)-3-hydroxy-16,17-epoxypregnan-20-one, also known as 17-hydroxyprogesterone, is a steroid hormone derived from the adrenal glands and gonads. It serves as a precursor for the synthesis of other steroid hormones, including cortisol and androgens, and is integral to the regulation of the menstrual cycle, fetal development during pregnancy, and the body's stress and inflammation response mechanisms.
Uses
Used in Pharmaceutical Industry:
(3beta,5beta,16alpha)-3-hydroxy-16,17-epoxypregnan-20-one is used as a medication for the treatment of hormone-related conditions such as congenital adrenal hyperplasia. It is utilized for its role in hormone regulation and its ability to address specific hormonal imbalances or deficiencies.
Used in Endocrinology:
In the field of endocrinology, (3beta,5beta,16alpha)-3-hydroxy-16,17-epoxypregnan-20-one is used as a therapeutic agent to support the regulation of the menstrual cycle and to ensure proper fetal development during pregnancy. Its involvement in the body's stress and inflammation response also makes it a valuable compound in managing related conditions.
Used in Research and Development:
(3beta,5beta,16alpha)-3-hydroxy-16,17-epoxypregnan-20-one is used as a key compound in research for understanding the complex interactions and roles of steroid hormones in the human body. It aids in the development of new treatments for various endocrine disorders and conditions related to hormonal imbalances.
Check Digit Verification of cas no
The CAS Registry Mumber 1044-90-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,0,4 and 4 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1044-90:
(6*1)+(5*0)+(4*4)+(3*4)+(2*9)+(1*0)=52
52 % 10 = 2
So 1044-90-2 is a valid CAS Registry Number.
1044-90-2Relevant articles and documents
-
Marker et al.
, p. 468 (1942)
-
Novel steroid inhibitors of glucose 6-phosphate dehydrogenase
Hamilton, Niall M.,Dawson, Martin,Fairweather, Emma E.,Hamilton, Nicola S.,Hitchin, James R.,James, Dominic I.,Jones, Stuart D.,Jordan, Allan M.,Lyons, Amanda J.,Small, Helen F.,Thomson, Graeme J.,Waddell, Ian D.,Ogilvie, Donald J.
supporting information; experimental part, p. 4431 - 4445 (2012/09/11)
Novel derivatives of the steroid DHEA 1, a known uncompetitive inhibitor of G6PD, were designed, synthesized, and tested for their ability to inhibit this dehydrogenase enzyme. Several compounds with approximately 10-fold improved potency in an enzyme assay were identified, and this improved activity translated to efficacy in a cellular assay. The SAR for steroid inhibition of G6PD has been substantially developed; the 3β-alcohol can be replaced with 3β-H-bond donors such as sulfamide, sulfonamide, urea, and carbamate. Improved potency was achieved by replacing the androstane nucleus with a pregnane nucleus, provided a ketone at C-20 is present. For pregnan-20-ones incorporation of a 21-hydroxyl group is often beneficial. The novel compounds generally have good physicochemical properties and satisfactory in vitro DMPK parameters. These derivatives may be useful for examining the role of G6PD inhibition in cells and will assist the future design of more potent steroid inhibitors with potential therapeutic utility.
